Particle.news

Download on the App Store

Trump DOJ Seeks Dismissal of States’ Challenge to FDA Abortion Pill Policy

The Department of Justice argues procedural flaws in Missouri, Idaho, and Kansas's lawsuit while facing Republican pressure to reverse its defense of mail-order abortion pill rules.

Image
Image
Pam Bondi, US attorney general, during a swearing-in ceremony in the Oval Office of the White House in Washington, DC, US, on Tuesday, May 6, 2025. Steve Witkoff, US special envoy to the Middle East, is pushing for progress on a deal for Hamas to release the remaining hostages before the end of Trump's tour of the Middle East, Israel's Channel 12 reported, a move that would break more than two months of deadlock. Photographer: Francis Chung/Politico/Bloomberg
Senator Josh Hawley (R-MO) speaks as Boeing President and CEO Dave Calhoun testifies during a Senate Homeland Security and Governmental Affairs Committee Investigations Subcommittee hearing to examine "Boeing's broken safety culture" on Capitol Hill in Washington, DC, June 18, 2024. (SAMUEL CORUM/AFP via Getty)

Overview

  • The Trump administration's DOJ has filed a motion to dismiss or transfer a lawsuit by Missouri, Idaho, and Kansas challenging FDA deregulation of mifepristone.
  • The DOJ contends that the states lack standing and that the Northern District of Texas is an improper venue for the case.
  • Sen. Josh Hawley has urged Attorney General Pam Bondi to reconsider defending Biden-era policies that expanded mail-order and telehealth access to mifepristone.
  • Anti-abortion leaders, including Kristen Waggoner and Marjorie Dannenfelser, argue that the Biden administration's policies have increased health risks for women and call for stricter regulations.
  • Mifepristone, which accounted for 63% of U.S. abortions in 2023, remains a focal point in broader debates over federal regulatory authority and state sovereignty.